Thursday, May 26, 2011

Outsourcing In The Pharma Industry

Little Blue Pill Vending Machine
It's seems as though a new strategy has emerged in the pharmaceutical industry to now outsource it's clinical trials work. According to a recent article posted on FierceBiotech, Pfizer is seeking to reduce it's clinical trials overhead by more than 9 billion dollars.
As Pfizer lays off thousands of R&D workers and scales back a research wing which consumed a whopping $9.4 billion last year, it's turning more to outside companies to handle trials rather than keep everything in house. Pfizer is following a path already blazed by rivals like Sanofi, which has developed a close relationship with Covance. And the change has helped drive a wave of consolidation in the CRO world as companies band together into large global operations that promise to provide a more efficient method for development as they compete for these exclusive deals.
But, as any cynical pharmacist might wonder, just how far will this outsourcing go in order to provide a more efficient method for generating pharma profits?

Image Artist: Penbender at

1 comment:

  1. finast 5 mg is a 5-alpha reductase inhibitor. It impedes an enzyme that is important to change testosterone to another hormone that makes the prostate develop. Thus, it assists with shrinking the prostate and soothes the side effects like difficulty in passing pee.